Annuncio • Jan 17
Hypha Labs, Inc. Auditor Raises 'Going Concern' Doubt Hypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Annuncio • Dec 31
Hypha Labs, Inc. announced delayed annual 10-K filing On 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Nov 07
Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 50,000,000
Price\Range: $0.21
Discount Per Security: $0.0095 Annuncio • Aug 15
Hypha Labs, Inc. announced delayed 10-Q filing On 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • May 16
Hypha Labs, Inc. announced delayed 10-Q filing On 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Jan 01
Hypha Labs, Inc. announced delayed annual 10-K filing On 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Nov 19
Hypha Labs, Inc. Announces Completion of Phase 1 of Its Facility and Arrival of V5 Working MicroPearls(TM) Prototypes Hypha Labs, Inc. announced it has completed Phase 1 of construction and design for its Research and Production facility in Las Vegas, Nevada as well as the arrival of its V5 MicroPearls prototype. Completion of Phase 1 at the facility is significant for a multitude of reasons, not least of which is it maintains the Company's anticipated timeline to begin roll-out of product sales in the fourth quarter of 2025. Secondly, the new facility allows the Company to expand and build upon its groundbreaking research which gives individuals the power to grow a broad array of functional mushrooms from the comfort and privacy of home in a predictable eight-day cycle. The advancements at the facility and in the V5 MicroPearls™ are significant: Facility Improvements and Additions: A new sterile clean room in the Las Vegas lab to accelerate its genetic experimentation work at Hyphalabs; Brand new mixing lab/kitchen for larger scale inventory management and personal; Newly upgraded data networks and communication equipment for the lab and offices, which allowed for more applied analysis and increases the efficacy of its Artificial Intelligence (AI) systems; Conference room upgrades to host meetings and large data screens for information sharing or other collaborative efforts; Prototyping equipment now online and built-out in its mechanical/electronic lab. This makes far more agile in its modification and enhancement efforts. The Arrival of Version 5 MicroPearls™ Mushroom Accelerator Prototypes: A new fleet of Version 5 MicroPearls™ prototypes has been delivered. V5 brings with it fully operational cloud-controlled microcontroller management in each bioreactor. This allows for consistent environmental profile control, motor controls, aeration controls, and more, all of which are now fully controlled and automated. The result is a more precise mushroom ingredient harvest for the home or Commercial operator. New Test Plans: New test plans will now be executed at a much higher rate, with more strains tested both at its internal Las Vegas facility and, thanks to its new video/data network, in collaboration with outside consultants. Annuncio • Jun 25
Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium Production Hypha Labs, Inc. announced the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Tradark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin. Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms as well. The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry. Annuncio • May 23
Hypha Labs, Inc. Announces New Patent Filing Hypha Labs, Inc. announced the initiation of a patent portfolio. This portfolio, spearheaded by an initial filing with the United States Patent and Trademark Office (USPTO) in March 2024, encompasses a series of inventive methods and devices designed to revolutionize the extraction of active components from mycelium, including psilocybin. These active components include psychedelic, functional and medicinal ingredients. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms. The pending patents cover the processing of mycelium, which is the vegetative part of fungi consisting of a network of thread-like hyphae, which holds immense potential in various industries including pharmaceuticals, nutraceuticals, and biotechnology. However, traditional methods of mycelium processing have often been hindered by lengthy cultivation periods and the requirement of growing mushrooms in soil over extended periods. Recognizing the need for innovation in this space, Hypha Labs, Inc. has developed pioneering techniques that bypass these limitations, offering a more efficient and sustainable approach to mycelium processing, including the growth and extraction of active psilocybin. At the heart of this patent portfolio lies a series of new and novel devices meticulously designed to organically extract desirable components from mycelium without the protracted timeline associated with traditional methods. Unlike conventional processes that necessitate the cultivation of mushrooms in soil over many months, proprietary technologies streamline the extraction process, enabling swift and efficient harvesting of mycelium's active constituents. In addition, the pending patents encompass a diverse range of devices, from large-scale industrial equipment to consumer-friendly appliances, all designed to facilitate the organic processing of mycelium with utmost efficiency and convenience. This includes devices for commercial production facilities and small table-top appliances for in-home consumer use. The devices covered by the pending patents will be for businesses and consumers alike for harnessing the full potential of mycelium and its components with ease. The significance of patents in this emerging field cannot be overstated. Patents play a crucial role in driving innovation and investment in scientific devices related to mycological sciences. They provide legal protection for groundbreaking technologies, incentivize collaboration, and facilitate the commercialization of novel solutions. Annuncio • May 17
Hypha Labs, Inc. announced delayed 10-Q filing On 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Apr 30
Hypha Labs, Inc. Appoints Craig Ellins as Chief Science Officer Hypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Sciences. His expertise in identifying and capitalizing on early-stage opportunities in new markets guides strategic direction. He is especially knowledgeable about the cannabis industry, which he psilocybin space is going to mirror. Annuncio • Aug 17
Digipath, Inc. announced delayed 10-Q filing On 08/15/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • May 17
Digipath, Inc. announced delayed 10-Q filing On 05/16/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Dec 31
Digipath, Inc. announced delayed annual 10-K filing On 12/30/2022, Digipath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Jan 01
DigiPath, Inc. announced delayed annual 10-K filing On 12/30/2020, DigiPath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Jul 07
DigiPath, Inc. Announces Resignation of Kyle Remenda as Chief Executive Officer On July 1, 2020 the Digipath, Inc. entered into a Separation and Release Agreement with Kyle Remenda, pursuant to which Mr. Remenda resigned from all of his positions with the Company and its subsidiaries, including his position as Chief Executive Officer of the Company. 